Trials / Terminated

TerminatedNCT00313274

Safety and Antiviral Activity Study of Clevudine 30 mg QD in Patients With HBeAg(-) Chronic HBV

A Double-Blind, Randomized, Parallel, Placebo-Controlled Phase III Study to Evaluate the Safety and Antiviral Activity of Clevudine (L-FMAU) 30 mg QD in Patients With HBeAg Negative Chronic Hepatitis B

Status: Terminated
Phase: Phase 3
Study type: Interventional
Enrollment: 80 (planned)

Sponsor: Bukwang Pharmaceutical · Industry
Sex: All
Age: 18 Years – 60 Years
Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine safety and efficacy of 30mg daily dose of clevudine (L-FMAU) at 24 weeks of treatment in chronic HBV infected patients with HBeAg negative

Conditions

Hepatitis B

Interventions

Type	Name	Description
DRUG	Clevudine

Timeline

Start date: 2003-07-01
Completion: 2004-12-01
First posted: 2006-04-12
Last updated: 2017-02-01

Locations

30 sites across 1 country: South Korea

Source: ClinicalTrials.gov record NCT00313274. Inclusion in this directory is not an endorsement.